Bayer Accelerates into CIIE Mode with Expanded Lineup of Debut Innovations Driving Upgraded Solutions
Bayer
Pharmaceutical Product R&D Developer
ShanghaiOctober 16, 2023PR Newswire -- The 6th China International Import Expo (hereinafter referred to as "CIIE") is about to commence, and Bayer, a globally renowned life sciences company, is actively preparing for the exhibition. Bayer will showcase its three divisions -- Pharmaceuticals (and Radiology), Consumer Health, and Crop Science -- for the sixth consecutive year. This year, under the theme of "Science Creates a Better Life+", Bayer will make appearances in both the Medical Devices and Healthcare Products展区 and the Crop Seed Industry专区, presenting innovative achievements across multiple fields while expanding its local "circle of friends" in China. Through concrete actions, Bayer is deepening its commitment in China.
"The CIIE, as an important platform for China to promote high-level opening up, fully demonstrates China's determination to open its market to the world and share 'Chinese opportunities' with the world. Over the past six years, the increasingly successful CIIE has provided multinational companies like Bayer with an important window to grasp the pulse of the Chinese market, promote exchanges and cooperation among all parties, and actively integrate into China's economic development."Xiaolan Zhou, Global Executive Vice President of Bayer AG's Pharmaceuticals Division and President of Bayer China, and President of Bayer Greater China"China has always been one of Bayer's most crucial strategic markets globally and also one of its most reliable and robust growth engines. This year, Bayer will continue to seize the 'CIIE opportunity,' further expand its booth area, fully leverage the all-round 'spillover effect,' showcase innovative achievements across multiple fields, establish various local partnerships, and strengthen exchanges and interactions with partners from all sectors."
Gather Innovative Achievements, Leverage the "Spillover Effects" of CIIE
Over the past five years, the China International Import Expo (CIIE) has continuously unleashed a powerful "spillover effect," becoming a "driver" and "incubator" for multinational companies to accelerate the introduction and implementation of innovative achievements. During this period, Bayer's innovation rally has been constantly sounding, bringing nearly 30 exhibits that are "global premieres," "China debuts," or "CIIE first-shows," and successfully incubating products including Kerendia.®, Little Elevit®, Ambition®Eight "CIIE Babies" including these products.
This year, Bayer's three major divisions will continue to present a number of leading innovative products and solutions, bringing more "first exhibitions" and "CIIE babies" results, looking forward to further leveraging their expertise to empower the Chinese people to create a healthier and better life.
In the prescription drug field, Bayer will introduce Verquvo for heart and kidney.®Hecsenda®、Nubeqa for prostate cancer treatment®, as well as Eylea in the ophthalmology field®Innovative products such as Verquvo.®(Vericiguat tablets) have been approved in China for the treatment of chronic heart failure, ushering in a new era of multi-pathway combination therapy for heart failure with its novel and unique mechanism of action. Also in the cardiovascular field, Bayer will introduce for the first time at the CIIE a重磅 oral anticoagulant drug under development – the oral Factor XIa inhibitor Asundexian. Kesenda®(Finerenone tablets) are the first non-steroidal, selective mineralocorticoid receptor antagonists approved for use in chronic kidney disease associated with type 2 diabetes, and were included in the National Medical Insurance Catalog in January this year. As for Nubeqo,®Following its debut as a star exhibit at the 4th CIIE after its initial approval, it was approved in China in March this year for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), covering the entire course of prostate cancer and benefiting more patients with prostate cancer. In addition, as the global leader in ophthalmology anti-VEGF treatment, Eylea...®(Aflibercept 2mg) will make its debut at a high dose of Aflibercept 8mg at the CIIE, bringing sustained optimal therapeutic benefits to patients with fundus diseases and ushering in a new era of anti-VEGF treatment.
In the field of imaging diagnostics, Bayer will present the China debut of two innovative products, namely the latest generation of the CT high-pressure injection system MEDRAD.®Stellant FLEX High-Pressure Injection System and MEDRAD MR High-Pressure Contrast Injection System Equipped with Workstation 3.0 New Module®MRXperion, which have been improved in terms of operational flexibility, safety, and cost-effectiveness to varying degrees, bring a better user experience.
The Consumer Health Division will showcase the latest innovations from many of its well-known brands at the CIIE, including: Dulcolax for issues such as lack of appetite and indigestion.®Compound Digestive Enzyme, containing four types of high-activity enzymes, with a patented microsphere structure that allows digestive enzymes to act directly on food, achieving dual-action digestion in the stomach and intestines; Belosin, which has passed clinical trials for infants and young children, providing 48-hour deep hydration from the inside out.®High-Moisture Lotion; Elevit Little Love with Quadruple Nutritional Gold Formula Safeguards Eye and Brain Development for Babies in China®Carefully selected DHA algae oil and Elevit, scientifically customized for the nutritional needs of infants and young children.®Infant Liquid Calcium. With an innovative product matrix covering multiple health categories and age groups, it provides diverse and more precise daily health management solutions for different populations.
Bayer Crop Science Division's three new corn varieties, live broadcast rice crop protection solutions, and the Bayer Learning Center will also make their first public debut at the CIIE. High-quality seed combinations and innovative customized solutions will meet the comprehensive planting needs of growers. Additionally, Bayer will focus on sustainability-related issues, showcasing the easyFlow M closed pesticide dosing and empty container cleaning device, as well as Phytobac.®Mini Shuilejie Pesticide Waste Liquid Treatment Device Demonstrates Commitment to Leading Regenerative Agriculture and Promoting Sustainable Development.
Expand Local Cooperation and Exchange, Share Development Opportunities
Apart from fully showcasing the company's innovative achievements, the CIIE also serves as an important platform for Bayer to expand its "circle of friends" in China and realize local cooperation and exchange in diverse fields. Over the past five years, Bayer has "formed many good relationships" at the CIIE, reaching nearly 20 significant agreements with local partners.
Continuing to drive innovation, this year Bayer looks forward to partnering with more local collaborators in China. It aims to further cooperate in the fields of chronic disease, daily health management, agriculture, and digitalization, joining hands with partners to build a collaborative network covering R&D, production, sales, services, and science popularization. While promoting high-quality development in China's healthcare and agricultural sectors, it seeks to better serve patients, consumers, and farmers in China.
Upgrade the Wonderful Interactive Experience, Look Forward to a Healthy and Bright Future
Bayer's Booth Showcases Numerous Highlight Products and Innovative Solutions While Offering a Series of Rich Booth Activities and Engaging Interactive Experiences to Unlock More Possibilities for a Healthy and Better Life. Over the past five years, Bayer has organized nearly 40 interactive events at the CIIE aimed at the public, including new product launches, science popularization lectures, themed salons, and free health checks, providing booth visitors with an experience that combines professionalism and fun.
Bayer's Booth Reaches New Record High at 700 Square Meters; "Seeing Vitality" Art Exhibition to Premiere at CIIE
The 6th CIIE is about to open, and Bayer has already secured a spot for the 7th CIIE in advance. Bayer looks forward to continuing to leverage the CIIE platform to focus on utilizing its expertise in healthcare and agricultural technology, enabling more innovative achievements to be implemented in China. Through practical actions, Bayer aims to contribute to China's ambitious goals of "Healthy China," "Rural Revitalization," "Common Prosperity," "Carbon Neutrality," and "Seed Industry Revitalization," empowering the Chinese people to create a better life.
(End)
About Bayer
Bayer, as a multinational enterprise, has core competitiveness in the fields of health and agriculture within the life sciences sector. The company is committed to helping people overcome major challenges brought about by the continuous growth and aging of the global population through its products and services, benefiting humanity and the prosperity of the planet. Bayer is dedicated to promoting sustainable development and having a positive impact on its business. At the same time, the group also enhances profitability and creates value through technological innovation and business growth. Globally, the Bayer brand represents trustworthiness, reliability, and high quality. In the 2022 fiscal year, Bayer had approximately 101,000 employees and sales of approximately 50.7 billion euros. Research and development investment, excluding special items, was approximately 6.6 billion euros. For more information, please seewww.bayer.com。
Forward-Looking Statements
This press release includes forward-looking statements by the management of Bayer AG based on current assumptions and forecasts. Various known and unknown risks, uncertainties, and other factors could cause the company's actual operational results, financial condition, development, or performance in the future to differ materially from the estimates made in the aforementioned forward-looking statements. These factors are disclosed on Bayer's official website.www.bayer.comIn the various reports published by Bayer. Bayer has no responsibility to update these forward-looking statements or to align them with future events or developments.